Katina Dorton

Katina Dorton is a current Mallinckrodt board member. Her qualifications to serve on the board include more than 30 years of experience in finance and healthcare, spanning fundraising, mergers and acquisitions, and business development. Ms. Dorton most recently served as Chief Financial Officer of NodThera, a private biotechnology company, from 2020 to 2022. Prior to that, she held CFO roles at Repare Therapeutics (2019–2020), AVROBIO (2017–2019), and Inmatics (2015–2017). Earlier in her career, she worked as a healthcare investment banker at Morgan Stanley and Needham, and practiced M&A and securities law at Sullivan and Cromwell. 

In addition to her role on the Mallinckrodt Board, Ms. Dorton currently serves as a director on the boards of Fulcrum Therapeutics, TScan Therapeutics, and Sonoma Bio, which she joined in 2020, 2021, and 2024, respectively. Previous board service includes Pandion Therapeutics (2020–2021, until its acquisition by Merck) and US Ecology (2015–2022, until its acquisition by Republic Services). 

She holds a Bachelor of Arts from Duke University, an MBA from George Washington University, and a Juris Doctor from the University of Virginia. She is also NACD Directorship Certified®.